Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 280-291

  Higa, Gerald M ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; GONADORELIN; HORMONE RECEPTOR; IMIDAZOLE DERIVATIVE; LETROZOLE; MEGESTROL ACETATE; MUTAGENIC AGENT; TAMOXIFEN; TRIAZOLE DERIVATIVE; VOROZOLE;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PREVENTION; CARCINOGENESIS; ESTROGEN SYNTHESIS; FEMALE; HUMAN; MEDICAL DECISION MAKING; MENOPAUSE; REVIEW;

EID: 0034005567     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.280.34879     Document Type: Review

References (127)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA 1999;49(1):8-31.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
3. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977; 1:1174-6.
4. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985;45:4454-9.
5. Henderson IC, Canellos GP. Cancer of the breast The past decade. N Engl J Med 1980;302:17-30, 78-90.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90(18):1371-88.
7. Santen RJ, Wells SA. The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 1980;46:1066-74.
8. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94:10937-42.
9. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997;57(24):5493-7.
10. Lippman M, Dickson R. Growth regulation of normal and malignant breast epithelium. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant diseases. Philadelphia: WB Saunders, 1991:363-94.
11. Kirschner MA. The role of hormones in the development of human breast cancer. In: McGuire WL, ed. Breast cancer 3: advances in research and treatment, current topics. New York: Plenum Press, 1979:199-226.
12. Segaloff A. Hormones and mammary carcinogenesis. In: McGuire WL, ed. Advances in research and treatment, experimental biology. New York: Plenum Press, 1978:1-22.
13. Lippman ME, Dickson RB. Growth control of normal and malignant breast epithelium. Prog Clin Biol Res 1990;354: 147-78.
14. Lippman ME, Bolan G. Oestrogen responsive breast cancer in long-term tissue culture. Nature 1975;256:592-3.
15. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48:417-28.
16. Bates SE, Davidson NE, Valverius EM, et al. Expression of transforming growth factor-alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988;2:543-5.
17. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12.
18. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272: 10882-94.
19. Kandouz M, Siromachkova M, Jacob D, Chretien-Marquet B. Antagonism between estradiol and progestin on bc1-2 expression in breast-cancer cells. Int J Cancer 1996;68:120-5.
20. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037-46.
21. Toniolo PG, Levita M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7
22. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
23. Veronesi U, Pizzocaro G, Rossi A. Oophorectomy for advanced carcinoma of the breast. Surg Gynecol Obstet 1975;141:569-70.
24. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988;109:219-28.
25. Ward HWC, Arthur K, Banks AJ, et al. Anti-oestrogen therapy for breast cancer - a report on 300 patients treated with tamoxifen. Clin Oncol 1978;4:11-17.
26. Jensen EV, DeSombre ER, Jungblut PW. Estrogen receptors in hormone-responsive tissues and tumors. In: Wissler RW, Dao TL, Wood S Jr, eds. Endogenous factors influencing host-tumor balance. Chicago: University of Chicago Press, 1967:15-30.
27. McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 1996;93:10069-73.
28. Kelloff GJ, Lubet RA, Fay JR, et al. Farnesyl protein transferase inhibitors as potential cancer chemoprevetives. Cancer Epidemiol Biomarkers Prev 1997;6:267-82.
29. Cocconi G, De Lisi V, Boni C, et al. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 1983;51:581-8.
30. Cavalli F, Beer M, Martz G, et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss group for clinical cancer research. Br Med J 1983;286:5-8.
31. Legha S, Buzdar AU, Smith TL, et al. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 1979;91:847-52.
32. Ahmann DL, Green SJ, Bisel HF, et al. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 1982;5:355-8.
33. Falkson G, Falkson HC, Glidewell O, et al. Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 1979;43:2215-22.
34. Taylor SG, Gelman RS, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage II breast cancer in elderly women. Ann Intern Med 1986;104:455-61.
35. Australian and New Zealand Breast Cancer Trials Group. Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 1986;4:186-93.
36. Kaufman RJ. Advanced breast cancer - additive hormonal therapy. Cancer 1981;47:2398-403.
37. Manni A, Trujillo JE, Marshall JS, et al. Anti-hormone treatment of stage IV breast cancer. Cancer 1979;43:444-50.
38. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38:4289-91.
39. LeClercq G, Heuson JC. Therapeutic significance of sex steroid hormone receptors in the treatment of breast cancer. Eur J Cancer 1977;13:1205-15.
40. Edwards DP, Chamness GC, McGuire WL. Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 1979;560:457-86.
41. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J Biol Chem 1978;253:2223-8.
42. Milgrom E, Luu Thi M, Atger M, Baulieu EE. Mechanisms regulating the concentration and the conformation of progesterone receptor(s) in the uterus. J Biol Chem 1973;248:6366-74.
43. Janne O, Kontula K, Luukkainen T, Vihko R. Oestrogen-induced progesterone receptor in human uterus. J Steroid Biochem 1975;6:501-9.
44. Leitzel K, Teramoto Y, Konrad K, et al. Elevated C-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
45. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25.
46. Elledge R, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology group study. Clin Cancer Res 1998;4:7-12.
47. Soubeyran I, Quenel N, Coindre JM, et al. pS2 Protein: a marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer. Br J Cancer 1996;74:1120-5.
48. Borg A, Baldetorp B, Ferno M, et al. C-erb B-2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
49. Carlomagno C, Perrone F, Gallo C, et al. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary node metastases. J Clin Oncol 1996;14:2702-8.
50. Desombre ER, Carbone PP, Jensen EV, et al. Special report. Steroid receptors in breast cancer. N Engl J Med 1979;301:1011-12.
51. Tumor Marker Guideline Panel of the American Society for Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
52. Fisher B, Fisher ER, Redmond C. Ten year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986;4:929-41.
53. Bonadonna G, Valagussa P, Rossi A, et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985;5:95-115.
54. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer . N Engl J Med 1976;297:405-10.
55. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: an overview of randomized trials. Lancet 1996;348:1189-96.
56. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy, 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
57. Early Breast Cancer Trialists' Collaborative Group. The effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
58. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:451-66.
59. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-9.
60. Swedish Breast Cancer Co-operative Group. Randomised trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
61. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors N Engl J Med 1989;320:479-84.
62. Goldhirsch A, Glick JH, Gelbeer RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-8.
63. Ingle JN, Krook JE, Green SJ, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986;4:178-85.
64. Buchanan RB, Blamey RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986;4:1326-30.
65. Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist, in the treatment of premenopausal patients with metastatic breast cancer: The German Zoladex trial group. J Clin Oncol 1989;7:1113-19.
66. Patterson JS. Nolvadex (tamoxifen) as an anticancer agent in humans. In: Sutherland RL, Jordan VC, eds. Non-steroidal antiestrogens: molecular pharmacology and antitumor activity. Sydney: Academic Press, 1981:453-71.
67. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995;55:3331-8.
68. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993;26:237-46.
69. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 1993;26:119-30.
70. Fuqua SAW, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem 1993;17G:194-7.
71. Nesto RW, Cady B, Oberfield RA, Pazianos AG, Salzman FA. Rebound response after estrogen therapy for metastatic breast cancer. Cancer 1976;38:1834-7.
72. Howell A, Dodwell DJ, Anderson H, Redford J. Response after withdrawal of tamoxifen and progesterones in advanced breast cancer. Ann Oncol 1992;3:611-17.
73. Canney PA, Griffiths T, Latief TN, Priestman TJ. Clinical significance of tamoxifen withdrawal response [letter]. Lancet 1987;1:36.
74. Thijssen JHH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989;25:1953-9.
75. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990;33:2933-42.
76. McNatty KP, Baird DT, Bolton A, Chambers P, Corker CS, MacLean H. Concentrations of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. J Endocrinol 1976;71:77-85.
77. Thompson EA, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatisation of androstenedione. J Biol Chem 1974;249:5364-72.
78. Ryan KJ. Biological aromatization of steroids. J Biol Chem 1959;234:268-72.
79. Siiteri PK. Review of studies on estrogen biosynthesis in the human. Cancer Res 1982;42:3269S-73.
80. Brodie A, Inkster S. Aromatase in the human testis. J Steroid Biochem Mol Biol 1993;44:549-55.
81. Naftolin F, Ryan KJ, Petro Z. Aromatization of androstenedione. J Clin Endocrinol Metab 1970;33:368-70.
82. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207-14.
83. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476-9.
84. Bulun SE, Simpson ER. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 1994;30:19-29.
85. Chen S, Besman MJ, Sparkes RS, et al. Human aromatase: cDNA cloning southern blot analysis, and assignment of the gene to chromosome 15. DNA Mol Biol 1988;7:27-38.
86. Siegelmann-Daniell N, Zhang JQ, McGlynn KA, Buetow KH. DNA-based variation at the aromatase gene (CYP19) and its role in breast cancer susceptibility [abstr]. Proc Am Assoc Cancer Res 1996;15:2004a.
87. Miller WR, Mullen P. Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 1993;44:597-604.
88. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25.
89. Santen RJ, Leszczynski D, Tilson-Mallet N, et al. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulphatase pathways. Ann NY Acad Sci 1986;464:126-37.
90. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 1991;39:783-90.
91. Durgam VR, Tekmal RR. The nature and expression of int-5, a novel MMTV integration locus gene in carcinogen-induced tumors. Cancer Lett 1994;87:179-86.
92. Diab SG, Castles CG, Fuqua SAW. Role of altered estrogen receptors in breast cancer. In: Vedeckis WV, ed. Hormones and cancer. Boston: Birkhauser, 1996:261-81.
93. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 1999;69:293-7.
94. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-15.
95. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
96. Hseuh AJW, Adashi EY, Jones PBC, Welsh TH Jr. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocrinol Rev 1984;5:76-127.
97. Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23(suppl 9):10-20.
98. Corbin CJ, Graham-Lorence S, McPhaul M, Mason JI, Mendelson CR, Simpson ER. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in non-steroidogenic cells. Proc Natl Acad Sci USA 1988;85:8948-53.
99. Nebert DW, Nelson DR, Coon MJ, et al. The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Mol Biol 1991;10:1-14.
100. Dowsett M, Stein RC, Mehta A, Coombes RC. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990;32:623-34.
101. Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990;62:679-83.
102. Dowsett M, Coombes RC. The development of the new aromatase inhibitor 4-OHA. Endocrine and clinical aspects, in Aromatase Inhibition: Past, Present, and Future Symposium. 15th International Cancer Congress, Hamburg, Germany, August 19, 1990. Geneva, Switzerland, International Union Against Cancer, 1990:9-10.
103. Possinger K, Jonat W, Hoffken K. Formestane in the treatment of advanced postmenopausal breast cancer. Ann Oncol 1994;5:S7-10.
104. Bajetta E, Zilembo N, Barni S, et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. Ann Oncol 1997;8:649-54
105. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
106. Buzdar AV, Jones SE, Plourde P, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1996;79:730-9.
107. Buzdar A, Smith R, Vogel C, et al. Fadrozole HC1 (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with melastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer 1996;77:2503-13.
108. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
109. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 1999;17:52-63.
110. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex study group. Cancer 1998;83:1142-52.
111. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9:639-45.
112. Perez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994;5(suppl 7):S19-24.
113. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988;30:311-14.
114. Osborne CK, Coronado EB, Robinson JP Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987;23:1189-96.
115. Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980;51:473-7.
116. Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 1982;55:718-22.
117. Allred DC, O'Connell P, Fuqua SAW. Biomarkers in early breast neoplasia. J Cell Biochem 1993;17G:125-31.
118. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA induced rat mammary carcinomata. Eur J Cancer 1975;12:419-24.
119. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
120. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988;27:721-8.
121. Horsley JS III, Alrich EM, Sears HF, Wright CB. Adrenalectomy for metastatic mammary cancer. Ann Surg 1971;173:906-12.
122. Pearson OH, Ray BS. Hypophysectomy in the treatment of metastatic mammary cancer. Am J Surg 1960;99:544-52.
123. Fracchia AA, Farrow JH, Miller TR, Tollefsen RH, Greenberg EJ, Knapper WH. Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg Gynecol Obstet 1971;133:241-6.
124. Peters WP, Rosner G, Vredenburgh J, et al. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstr]. Proc Am Soc Clin Oncol 1999;18:2a.
125. Bergh J, and the Scandinavian Breast Cancer Study Group. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstr]. Proc Am Soc Clin Oncol 1999;18:3a.
126. Stadtmauer EA, and the Philadelphia Intergroup Study. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy [abstr]. Proc Am Soc Clin Oncol 1999;18:1a.
127. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer. Results of the French protocol PEGASE [abstr]. Proc Am Soc Clin Oncol 1999;18:161a.